Insider Buying Update for Tuesday, November 18: ALMS, LINE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy ALMS?
Source: NASDAQ.COM
Srinivas Akkaraju's Investment: Srinivas Akkaraju purchased 276,179 shares of Alumis (ALMS) at $5.25 each, totaling $1.45 million, and is currently up about 20% based on recent trading highs.
Previous Purchase by Akkaraju: Prior to this investment, Akkaraju bought shares worth $1.48 million at $4.61 each within the past year.
Robb A. Lemasters' Investment: Chief Financial Officer Robb A. Lemasters acquired 30,000 shares of Lineage for $1.01 million at a price of $33.74 per share.
Market Performance: Alumis shares are up approximately 8.6% on the day, while Lineage shares have increased by about 1.1%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALMS
Wall Street analysts forecast ALMS stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 23.070
Low
32.00
Averages
37.57
High
50.00
Current: 23.070
Low
32.00
Averages
37.57
High
50.00
About ALMS
Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of ESK-001 for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis and Parkinson’s Disease. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alumis Reports 2025 Fiscal Year Financial Results
- Reduced Net Loss: Alumis reported a net loss of $243.3 million for the fiscal year ending December 31, 2025, an improvement from a net loss of $294.2 million in 2024, indicating progress in cost control and operational efficiency despite ongoing financial pressures.
- Revenue Misses Expectations: The fiscal year 2025 revenue of $24.05 million fell short of market expectations by $0.23 million, suggesting challenges in sales and marketing efforts that impacted overall financial performance.
- Strong Cash Reserves: As of December 31, 2025, Alumis held $308.5 million in cash, cash equivalents, and marketable securities, reflecting robust liquidity that supports future R&D and market expansion initiatives.
- Active Financing Activities: Alumis recently priced a $300 million upsized public offering, demonstrating market confidence in its future prospects while providing additional capital to support its research advancements in psoriasis treatment.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: The changes in analyst ratings may lead to short-term volatility in the respective stocks, prompting investors to monitor these shifts closely to optimize their portfolios, especially in the current market environment.
- Impact of Rating Changes: Upgrades or downgrades in ratings typically have a direct effect on stock performance, necessitating that investors stay alert to these changes to timely adjust their investment strategies.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for more in-depth market insights.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics Overview: While specific stock names are not mentioned, such rating changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Investor Focus: For those considering buying ALMS stock, analysts' opinions will serve as a crucial reference point, potentially affecting their buying decisions and overall market sentiment.
- Data Source Note: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions while reminding investors to approach market analyses and recommendations with caution.
See More
BML Capital Management Fully Exits Alumis Stake
- Exit Transaction: On February 2, BML Capital Management disclosed in an SEC filing that it completely liquidated its 1,210,415 shares of Alumis for approximately $4.83 million, resulting in a significant reduction in its quarter-end position value, highlighting its risk management strategy regarding the stock.
- Market Performance: As of February 2, Alumis shares were priced at $26.42, reflecting a staggering 255.1% increase over the past year, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market confidence in its clinical-stage therapies.
- Company Overview: Alumis focuses on developing clinical-stage therapies for autoimmune and neuroinflammatory disorders, particularly TYK2 inhibitors, and despite reporting a net loss of $245.15 million, its R&D pipeline suggests substantial market potential.
- Investor Insight: BML's exit serves as a reminder that disciplined portfolio decisions can be impacted by fast-moving market catalysts, as Alumis's subsequent financing activities alleviated capital risk and reversed market sentiment, illustrating the dynamic nature of the biotech sector.
See More
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
- Market Surge: U.S. stocks rose significantly on Monday, with the Dow Jones index gaining over 350 points, indicating strong investor confidence and potentially attracting more capital into the market.
- Peakstone Realty Trust Price Surge: Shares of Peakstone Realty Trust soared 32.5% to $20.70 on Friday, reflecting positive market sentiment regarding the company's future prospects and the anticipated benefits of the acquisition.
- Acquisition Announcement: Brookfield announced plans to acquire Peakstone Realty Trust in a $1.2 billion all-cash deal, which not only enhances Brookfield's asset portfolio but also signals its strategic intent to expand further in the real estate sector.
- Positive Market Reaction: Following the acquisition news, Peakstone Realty Trust's stock price surged, indicating strong investor confidence in the deal and potentially attracting additional investment into the company.
See More
Alumis Reports 2025 Fiscal Year Financial Results
- Reduced Net Loss: Alumis reported a net loss of $243.3 million for the fiscal year ending December 31, 2025, an improvement from a net loss of $294.2 million in 2024, indicating progress in cost control and operational efficiency despite ongoing financial pressures.
- Revenue Misses Expectations: The fiscal year 2025 revenue of $24.05 million fell short of market expectations by $0.23 million, suggesting challenges in sales and marketing efforts that impacted overall financial performance.
- Strong Cash Reserves: As of December 31, 2025, Alumis held $308.5 million in cash, cash equivalents, and marketable securities, reflecting robust liquidity that supports future R&D and market expansion initiatives.
- Active Financing Activities: Alumis recently priced a $300 million upsized public offering, demonstrating market confidence in its future prospects while providing additional capital to support its research advancements in psoriasis treatment.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: The changes in analyst ratings may lead to short-term volatility in the respective stocks, prompting investors to monitor these shifts closely to optimize their portfolios, especially in the current market environment.
- Impact of Rating Changes: Upgrades or downgrades in ratings typically have a direct effect on stock performance, necessitating that investors stay alert to these changes to timely adjust their investment strategies.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for more in-depth market insights.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these firms.
- ORCL Stock Outlook: Analysts have provided their latest views on ORCL stock for potential buyers, which could influence investor decisions and market sentiment regarding the stock.
- Market Dynamics Overview: The backdrop for these rating changes is a shifting market environment, with analysts evaluating based on the latest financial data and industry trends, indicating a cautious outlook on the overall market.
- Investor Focus: Investors should pay attention to these rating changes as they may impact stock price volatility and investment strategies for the affected companies, particularly in an uncertain economic climate.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics Overview: While specific stock names are not mentioned, such rating changes typically have a direct impact on the stock prices of the affected companies, prompting investors to closely monitor these shifts to optimize their portfolios.
- Investor Focus: For those considering buying ALMS stock, analysts' opinions will serve as a crucial reference point, potentially affecting their buying decisions and overall market sentiment.
- Data Source Note: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions while reminding investors to approach market analyses and recommendations with caution.
See More
BML Capital Management Fully Exits Alumis Stake
- Exit Transaction: On February 2, BML Capital Management disclosed in an SEC filing that it completely liquidated its 1,210,415 shares of Alumis for approximately $4.83 million, resulting in a significant reduction in its quarter-end position value, highlighting its risk management strategy regarding the stock.
- Market Performance: As of February 2, Alumis shares were priced at $26.42, reflecting a staggering 255.1% increase over the past year, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market confidence in its clinical-stage therapies.
- Company Overview: Alumis focuses on developing clinical-stage therapies for autoimmune and neuroinflammatory disorders, particularly TYK2 inhibitors, and despite reporting a net loss of $245.15 million, its R&D pipeline suggests substantial market potential.
- Investor Insight: BML's exit serves as a reminder that disciplined portfolio decisions can be impacted by fast-moving market catalysts, as Alumis's subsequent financing activities alleviated capital risk and reversed market sentiment, illustrating the dynamic nature of the biotech sector.
See More
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
- Market Surge: U.S. stocks rose significantly on Monday, with the Dow Jones index gaining over 350 points, indicating strong investor confidence and potentially attracting more capital into the market.
- Peakstone Realty Trust Price Surge: Shares of Peakstone Realty Trust soared 32.5% to $20.70 on Friday, reflecting positive market sentiment regarding the company's future prospects and the anticipated benefits of the acquisition.
- Acquisition Announcement: Brookfield announced plans to acquire Peakstone Realty Trust in a $1.2 billion all-cash deal, which not only enhances Brookfield's asset portfolio but also signals its strategic intent to expand further in the real estate sector.
- Positive Market Reaction: Following the acquisition news, Peakstone Realty Trust's stock price surged, indicating strong investor confidence in the deal and potentially attracting additional investment into the company.
See More
